An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

This study has been completed.
Information provided by:
FDA Office of Orphan Products Development Identifier:
First received: January 30, 2002
Last updated: March 24, 2015
Last verified: January 2002
This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.

Condition Intervention Phase
Neurofibromatosis 2
Device: Penetrating auditory brainstem implant
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Open Label
Primary Purpose: Treatment
Official Title: Penetrating Auditory Brainstem Implant for Neurofibromatosis 2

Resource links provided by NLM:

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 10
Study Start Date: September 2001
Estimated Study Completion Date: August 2003
Detailed Description:

Neurofibromatosis Type 2 (NF2) is characterized by multiple tumors of the cranial and spinal nerves, and, in particular, by bilateral acoustic tumors. Surgical resection of these tumors generally results in the transection of the VIIIth nerve, destruction of the cochlea and auditory nerve, and total hearing loss. Due to the loss of the auditory nerve, these patients are not candidates for cochlear implantation. The Auditory Brainstem Implant (ABI) provides the only available intervention to restore some auditory sensation to these patients. An ABI is an implantable prosthesis that produces sound sensation by electrical stimulation of the ascending auditory pathway at the level of the cochlear nucleus.

The PABI may be placed surgically during tumor resection. Efficacy will be assessed using psychophysical and standard speech reception measures.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Diagnosis of neurofibromatosis type 2
  • Speak English as a primary language

Exclusion criteria:

  • Physical, psychological, or medical conditions that contraindicate the surgical procedure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00030043

United States, California
House Ear Institute
Los Angeles, California, United States, 90057
Huntington Medical Research Institutes
Pasadena, California, United States
United States, Colorado
Cochlear Corporation
Englewood, Colorado, United States
Sponsors and Collaborators
FDA Office of Orphan Products Development
  More Information Identifier: NCT00030043     History of Changes
Other Study ID Numbers: FD-R-001969-01 
Study First Received: January 30, 2002
Last Updated: March 24, 2015
Health Authority: United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
Electric Stimulation
Implants, Artificial
Speech Perception

Additional relevant MeSH terms:
Neurofibromatosis 2
Cranial Nerve Diseases
Cranial Nerve Neoplasms
Ear Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplastic Syndromes, Hereditary
Nerve Sheath Neoplasms
Nervous System Diseases
Nervous System Neoplasms
Neurocutaneous Syndromes
Neurodegenerative Diseases
Neuroectodermal Tumors
Neuroendocrine Tumors
Neuroma, Acoustic
Neuromuscular Diseases
Otorhinolaryngologic Diseases
Otorhinolaryngologic Neoplasms
Peripheral Nervous System Diseases
Peripheral Nervous System Neoplasms
Retrocochlear Diseases
Vestibulocochlear Nerve Diseases processed this record on May 23, 2016